StockNews.com Initiates Coverage on Otonomy (NASDAQ:OTIC)
StockNews.com Initiates Coverage on Otonomy (NASDAQ:OTIC)
StockNews.com began coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday morning. The firm issued a hold rating on the biopharmaceutical company's stock.
StockNews.com 开始报道的股票 Otonomy(纳斯达克股票代码:OTIC — 获取评级) 在周六上午发给投资者的研究报告中。该公司对这家生物制药公司的股票发布了持有评级。
Otonomy Price Performance
Otonomy 价格表现
Shares of NASDAQ:OTIC opened at $0.11 on Friday. The business's 50 day moving average price is $0.10 and its 200-day moving average price is $0.19. The firm has a market capitalization of $7.33 million, a price-to-earnings ratio of -0.14 and a beta of 1.55. Otonomy has a 1 year low of $0.06 and a 1 year high of $2.59.
纳斯达克:OTIC 的股价周五开盘价为 0.11 美元。该公司的50天移动平均线价格为0.10美元,其200天移动平均线价格为0.19美元。该公司的市值为733万美元,市盈率为-0.14,beta值为1.55。Otonomy创下1年低点0.06美元,1年高点2.59美元。
Institutional Inflows and Outflows
机构流入和流出
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OTIC. Two Sigma Investments LP lifted its holdings in Otonomy by 129.2% in the 3rd quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 80,153 shares in the last quarter. Requisite Capital Management LLC purchased a new position in shares of Otonomy during the 3rd quarter worth $44,000. State Street Corp raised its holdings in shares of Otonomy by 5.1% during the 1st quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock worth $437,000 after acquiring an additional 8,839 shares during the period. Lynx1 Capital Management LP raised its holdings in shares of Otonomy by 7,609.6% during the 3rd quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock worth $682,000 after acquiring an additional 2,282,880 shares during the period. Finally, Point72 Asset Management L.P. purchased a new position in shares of Otonomy during the 3rd quarter worth $1,621,000. Hedge funds and other institutional investors own 41.23% of the company's stock.
一些对冲基金和其他机构投资者最近增加了或减少了在OTIC的股份。Two Sigma Investments LP在第三季度将其在Otonomy的持股量提高了129.2%。Two Sigma Investments LP在上个季度又购买了80,153股股票后,现在拥有这家生物制药公司142,183股股票,价值42,000美元。Requiend Capital Management LLC在第三季度购买了价值44,000美元的Otonomy股票的新头寸。State Street Corp在第一季度将其持有的Otonomy股票提高了5.1%。State Street Corp在此期间又收购了8,839股股票后,现在拥有这家生物制药公司的182,239股股票,价值43.7万美元。Lynx1 Capital Management LP在第三季度将其持有的Otonomy股票增加了7,609.6%。在此期间又收购了2,282,880股股票后,Lynx1 Capital Management LP现在拥有这家生物制药公司的2312,880股股票,价值68.2万美元。最后,Point72 Asset Management L.P. 在第三季度购买了价值16.1万美元的Otonomy股票的新头寸。对冲基金和其他机构投资者拥有该公司41.23%的股票。
Otonomy Company Profile
Otonomy 公司简介
(Get Rating)
(获取评分)
Otonomy, Inc operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.
Otonomy, Inc是一家生物制药公司。从事神经病学疗法的开发。该公司的产品线包括OTIVIDEX(地塞米松)梅尼尔病、OTIPRIO(环丙沙星视力悬浮液)急性带管中耳炎(AOMT)、OTO-313(加环素)耳鸣、OTO-413(BDNF)隐性听力损失、OTO-510(耳保护剂)预防CIHL、OTO-6XX(毛细胞再生)严重听力损失。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- Molson Coors: Time To Buy More Or Tap Out?
- Medtronic Stock, A Bottom Is In Play
- What Are Dividend Payment Dates?
- Home Depot Is Heading For The Bargain Basement, Be Ready
- These Stocks Will be Dividend Aristocrats in Five Years or Less
- 免费获取 StockNews.com 关于自主学的研究报告(OTIC)的副本
- Molson Coors:是时候多买还是下水了?
- 美敦力股票,触底在起作用
- 什么是股息支付日期?
- Home Depot 要去便宜的地下室了,做好准备
- 这些股票将在五年或更短的时间内成为股息贵族
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Otonomy Daily 的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Otonomy及相关公司的最新新闻和分析师评级的简明每日摘要。